DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 586
- Registration Number
- NCT05338970
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇯🇵Kurume University Hospital, Kurume, Japan
🇮🇹Ospedale Santa Maria della Misericordia, Perugia, Italy
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 187
- Registration Number
- NCT05280470
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana-Faeber Cancer Institute, Boston, Massachusetts, United States
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 740
- Registration Number
- NCT05215340
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille Cedex 9, France
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC, Freehold, New Jersey, United States
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 80
- Registration Number
- NCT05203692
- Locations
- 🇺🇸
Apex Clinical Research (Collaborative Neuroscience Research), Long Beach, California, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 3300
- Registration Number
- NCT05120895
- Locations
- 🇰🇷
Inje University Haeundae Paik Hospital - Site 0031, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital - Site 0033, Busan, Korea, Republic of
🇰🇷Hallym University Medical Center - Chuncheon, Chuncheon, Korea, Republic of
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2972
- Registration Number
- NCT05107063
- Locations
- 🇰🇷
Dongguk University Ilsan Hospital, Goyang, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Daegu, Korea, Republic of
🇰🇷HANIL General Hospital, Seoul, Korea, Republic of
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT05025722
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8
- Registration Number
- NCT04796831
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 5000
- Registration Number
- NCT04747496
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Changzhou No.2 People'S Hospital, Changzhou, Jiangsu, China
🇨🇳Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 122
- Registration Number
- NCT04744831
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States